Document is current
Any future updates will be listed below
-
Authors
Yoshinami, Tetsuhiro https://orcid.org/0009-0000-8747-3641
Shibata, Nobuhiro https://orcid.org/0000-0001-8647-5098
Tamaki, Kentaro
Ishimaru, Kentaro
Ito, Satoru
Nukada, Tomoyuki
Ohno, Shinji https://orcid.org/0000-0003-2093-3353
-
Funding
Funding for this research was provided by:
Kyowa Kirin Co,. Ltd.
- License Information
-
More Information
Article History
Received: 18 February 2025
Accepted: 26 April 2025
First Online: 19 May 2025
Declarations
:
: T Yoshinami has received speaker honoraria from Kyowa Kirin Co., Ltd., Chugai Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., MSD K.K., Eisai Co., Ltd., AstraZeneca K.K., and Pfizer Japan Inc. N Shibata received consulting fees for Advisory Board from Kyowa Kirin Co., Ltd., and Daiichi Sankyo Co., Ltd., and honoraria from Kyowa Kirin Co., Ltd., MSD K.K., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Pfizer Japan Inc., Eisai Co., Ltd., Taiho Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Nippon Kayaku Co., Ltd., Merck Biopharma Co., Ltd., and Bristol Myers Squibb K.K., and research funding from Daiichi Sankyo Co., Ltd., MSD K.K., and AstraZeneca K.K. K Tamaki has no competing interest to declare. K Ishimaru, S Ito and T Nukada are employees of Kyowa Kirin Co., Ltd. S Ohno has received speaker honoraria from Kyowa Kirin Co., Ltd, Eli Lilly Japan K.K., Chugai Pharmaceutical Co., Ltd., MSD K.K., and Nippon Kayaku Co., Ltd.
: The study protocol was approved by the Research Institute of Healthcare Data Science (RI2021015). According to the “Ethical Guidelines for Medical and Health Research Involving Human Subjects”, a study using secondary data stored in an anonymized structured format, such as this study, is outside the scope of the guidelines. Informed consent was not required for this study.
: Not applicable.
: Not applicable.
